Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × NETWORK × Serotonin Syndrome × Clear all

Phase

Status

Sponsor Class

OTHER 3 NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 12 Ovarian Neoplasms 7 Colorectal Neoplasms 7 Carcinoma, Non-Small-Cell Lung 7 Squamous Cell Carcinoma of Head and Neck 6 Prostatic Neoplasms 6 Lung Neoplasms 6 Neoplasm Metastasis 5 Fallopian Tube Neoplasms 5 Carcinoma, Ovarian Epithelial 5 Uterine Cervical Neoplasms 4 Sarcoma 4 Lymphoma 4 Head and Neck Neoplasms 4 Stomach Neoplasms 3 Rectal Neoplasms 3 Neuroectodermal Tumors, Primitive, Peripheral 3 Neoplasms 3 Leukemia, Myeloid, Acute 3 Leukemia 3 HIV Infections 3 Colonic Neoplasms 3 Central Nervous System Neoplasms 3 Carcinoma, Renal Cell 3 Burkitt Lymphoma 3 Unspecified Adult Solid Tumor, Protocol Specific 2 Tongue Neoplasms 2 Sezary Syndrome 2 Salivary Gland Neoplasms 2 Rhabdoid Tumor 2

Interventions

telotristat ethyl 1 lanreotide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04065165 2020-02-05

TELEFIRST

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3 Withdrawn

Carcinoid Heart Disease, Serotonin Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡